Royalty Report: Drugs, Antibiotic, Diagnostic – Collection: 268565

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Antibiotic
  • Diagnostic
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 268565

License Grant
The joint effort will use the Parties technologies for the high-throughput characterization of novel
antiinfective drug targets and rational drug design.

Licensor grants:
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Licensee Programs during the Research Term;
—  a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Licensee Products in the Field; and
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.

License Property
Licensor is engaged in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.

Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.

Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.

Field of Use
Field shall mean the treatment, prevention or diagnosis of bacterial or fungal infections.   As a result of the collaboration, the companies expect to accelerate the discovery of novel classes of antibiotics to treat infectious diseases, including those resistant to current therapies.

IPSCIO Record ID: 266779

License Grant
The joint effort will use the Parties technologies for the high-throughput characterization of novel
antiinfective drug targets and rational drug design.

Licensor grants:
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Cubist Programs during the Research Term;
—  a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to perform development activities for Shared Programs after designation of IND Candidates for such Shared Programs, to develop Licensee Products, and to make, have made, use, sell, have sold, offer for sale and import Shared Products and Licensee Products in the Field; and
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.

License Property
Licensor has developed expertise and proprietary technology in the areas of structural proteomics and high-throughput rational drug design.

Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.

Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.

Field of Use
Field shall mean the treatment, prevention or diagnosis of bacterial or fungal infections.   As a result of the collaboration, the companies expect to accelerate the discovery of novel classes of antibiotics to treat infectious diseases, including those resistant to current therapies.

IPSCIO Record ID: 266778

License Grant
Licensor grants a worldwide, exclusive license with the right to grant sublicenses, under Licensors interest in Research Patents, Licensors Process Technology and Licensors Background Patents to develop, register, use, make, have made, import, export, offer to sell, and sell Licensees Products.
License Property
Licensor Background Patents relate to a biocatalytic process.

Licensees Product means either a Licensor Derivative Product which is a product for the making, using, selling, offering for sale, or import of which would, but for the licenses granted herein, infringe a valid claim of a Research Patent or that includes a Licensor Derivative; or Licensee Derivative Product which is a product containing a Licensee Derivative.

Licensor Derivative means a compound(s) prepared by Licensor pursuant to the Research Program and that is either a derivative of daptomycin created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, or a derivative of any such derivative created utilizing synthesis or biocatalysis technology developed or practiced by Licensor, and/or compound(s) prepared by Licensee or its Affiliates or Sublicensees that are simple esters or salts of compounds.

Biocatalytic process means biocatalytic procedure or biocatalysis used by Licensor to prepare derivatives of daptomycin and, without limitation, any process or procedure using organisms, catalysts, whether whole cell or isolated enzyme-based, strains, vectors, proprietary catalyst  preparation procedures, aqueous buffers or organic solvents, modifiers and enzyme cofactors.

Field of Use
Licensee is engaged in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections, including those caused by bacteria and fungi resistant to commercially available drugs.

Licensor will use its proprietary combinatorial biocatalysis technology to create derivatives of lipopeptides, a novel class of anti-infectives.  And Licensee is currently developing Cidecin® (daptomycin for injection)–the first investigational antibiotic derived from this new class.

IPSCIO Record ID: 148591

License Grant
Licensor grants the exclusive, worldwide license or sublicense, as the case may be, including the right to grant sublicenses, to manufacture, use, offer for sale, sell or import Licensed Products.
License Property
The Licensed Product means any Product, the manufacture, use, offer for sale, sale or import of which would infringe the Patent Rights in the absence of a license or sublicense for antibacterial agents having the same mechanism of action or pharmacophores acting on a given target.

Party established a collaboration to utilize bacterial genetic approaches with in vitro essential genes to discover products for the treatment of bacterial infections in animals.

Field of Use
The products are for Dogs, Cats, Horses and Livestock.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.